Page 35
Figure 31 : Challenges to adoption for PT
Source : goetzpartners Research
Established PT system manufacturers look set to retain their grip on the market
Future Outlook
The future of PT Long-term , we predict PT will eventually replace photon RT as the SoC , however this is unlikely to be implemented in any imminent time frame . Authorities are commissioning the integration of PT in UK , Europe , and the US , however the limited number of centres means treatment is prioritised for children , to avoid life-long complications as they typically respond worse to RT , and complex and sensitivelyplaced tumours – particularly those in the central nervous system . The main driver of innovation for PT is reducing the footprint of new systems , allowing easier implementation of PT in centres given the complexity of installing a full , often , multi-room PT system complete with a cyclotron or a synchrotron . Varian , acquired by Siemens Healthineers in April 2021 , are a leading developer of PT systems , initially developing the ProBeam system , which is being integrated in RT centres , have installed their first ProBeam 360 system in February 2021 in Lancaster , PA ( US ), which improves TPS and reduces footprint of installation . Other companies developing novel proton therapies often fail to demonstrate capabilities of implementing machines for commercial use , hindering the progress of PT . Mevion and Hitachi are other market leaders in compact PT systems , so far delivering 11 and 19 systems worldwide respectively . Hitachi are increasingly expanding their presence ex . Japan , adding to the 13 proton facilities based there , with 6 operational facilities in Europe and the US , and another 8 global sites under construction .
Please see analyst certifications , important disclosure information , and information regarding the status of analysts on pages 91-94 of this research report .